Clinical Trial Update: A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating regorafenib plus Envafolimab for metastatic Gastrointestinal Stromal Tumors with KIT exon 17 mutation after failure of st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Envafolimab (envafolimab)
• Regorafenib (regorafenib)

Snippet

Sponsor: Peking University | Conditions: Metastatic Gastrointestinal Stromal Tumors (GIST) | Phase 2 | Status: NOT_YET_RECRUITING